About wpadmin

This author has not yet filled in any details.
So far wpadmin has created 83 blog entries.

Biologics are a success factor according to Lipum

News: Umeå, 23 February 2021. Article in Biostock Lipum develops a new biological drug for chronic inflammatory diseases. According to one study, the probability for approval of biological drugs is almost twice as high as that of small molecules (new molecular entities, NME). This bodes well for Lipum’s drug candidate SOL-116, which is an antibody. [...]


Lipum planerar notering vid Nasdaq First North

Pressmeddelande: Umeå, 28 januari, 2021. Lipum AB med säte i Umeå grundades år 2010. Nu förbereds kapitalanskaffning genom en notering förutsatt godkänd ansökan vid Nasdaq First North Growth Market under våren 2021. Lipum har anlitat G&W Fondkommission att bistå bolaget i processen. Lipum har utvecklat läkemedelskandidaten SOL-116 som har en ny verkningsmekanism med möjlighet att [...]


Marina Norberg new CFO at Lipum

Press release: Umeå, January 26, 2020. Lipum AB has appointed Marina Norberg Chief Financial Officer (CFO). Marina Norberg has extensive experience as an approved auditor at PwC and as authorized accounting consultant within Aspia AB, the management team of which she belonged. Marina Norberg will report to CEO Einar Pontén and be part of Lipum's [...]


Lipum to carry out an IPO during 2021

News: Umeå, 19 January 2021. Article in Biostock Currently Lipum is planning an IPO (Initial Public Offering) to finance the start of the clinical trials required to take SOL-116 all the way to an approved biological drug. See this article from BioStock »  


Kallelse till extra bolagsstämma för ändring till publikt aktibolag

Pressmeddelande: Umeå, 15 December 2020. Kallelse till extra bolagsstämma i Lipum AB för ändring till publikt aktiebolag. Aktieägarna i Lipum AB, org.nr 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 29 december 2020. Den extra bolagsstämman hålls för att besluta om styrelsens förslag till fondemission samt ändring av bolagsordningen. Syftet med fondemissionen är att höja [...]



In the magazine "Skelett och ledhälsa” our founders Professor Olle Hernell, Dr. Susanne Lindquist and Professor Lennart Lundberg were interviewed about our drug candidate SOL-116. SOL-116 is the antibody that we have developed for the treatment of chronic inflammatory diseases and we are now moving towards an IPO to secure the financing for further progress. [...]



At Biostock Life Science Summit last week our CEO Einar Pontén presented the recent progress in bringing our lead candidate SOL-116 towards clinical verification. He also briefly described Lipum’s strategy to pre-clinically explore a palette of chronic inflammatory conditions in parallel. Altogether it will constitute a solid platform for partnering and a [...]

Go to Top